Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 14, Number 2—February 2008

Research

Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic

M. Ruby Siddiqui*Comments to Author  and W. John Edmunds*
Author affiliations: *Health Protection Agency, London, UK;

Main Article

Table

Total NHS costs and QALY loss (discounted at 3.5%) resulting from an influenza pandemic occurring in 30 years assuming 1918 or 1957/69 CFR*

Treatment program Pandemic influenza cases (millions) Pandemic influenza deaths (millions) Discounted NHS costs (million £) Discounted QALY loss (millions) Incremental cost per QALY (£)
1918 scenario
No intervention 15 0.344 113 2.23
Treat only 15 0.236 1,361 1.56 1,861†
Test-treat 15 0.231 2,356 1.53 31,031‡
1957–69 scenario
No intervention 15 0.044 113 0.395
Treat only 15 0.030 1,361 0.303 13,668†
Test-treat 15 0.030 2,356 0.299 227,896‡

*NHS, National Health Service; QALY, quality-adjusted life years; CFR, case-fatality ratio.
†Cost per QALY gained over no intervention program.
‡Cost per QALY gained over treat-only program.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO